A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin

Bone Marrow Transplantation

Volumn 22, Issue 7, 1998, Pages 685-688

  Birch, R ^a   Weaver, C H ^a   Carson, K ^a   Buckner, C D ^a,b  

^a Response Oncology Inc   (United States)

^b Response Oncology Inc   (United States)

Author keywords

Granisetron; High dose chemotherapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANISETRON; LORAZEPAM; THIOTEPA;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SELF ADMINISTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VOMITING;

EID: 0031791657     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701412     Document Type: Article

References (14)

1. Weaver C, Birch R, Schwartzberg L, West W. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic Publishers: Boston, MA, 1995, pp 59-85.
2. Antman K, Rowlings P, Vaughan W et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
3. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661-670.
4. Weaver CH, Schwartzberg LS, Hainsworth J et al. Treatment related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997; 19: 671-678.
5. Yarker Y, McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994; 48: 761-793.
6. Carmichael J, Bessell E, Harris A et al. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer 1994; 70: 1161-1164.
7. Latreille J, Stewart D, Laberge F et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer 1995; 3: 307-312.
8. Hunter A, Prentice H, Pothecary K et al. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 1991; 7: 439-441.
9. The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990; 8: 563-564.
10. The Granisetron Study Group. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol 1993; 119: 555-559.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Royal Stat Soc 1972; 135: 185-198.
13. Hacking A. Oral granisetron - simple and effective: a preliminary report on behalf of the Granisetron Study Group. Eur J Cancer 1992; 28A: S28-S32.
14. Johnsonbaugh R, Mason BA, Friedman C et al. Oral granisetron is an effective anti-emetic in patients receiving moderately emetogenic chemotherapy. Am Soc Clin Oncol 1994; 13: 437.